Find a Clinical Trial

Showing 1 - 10 out of 19

OCEANIC-STROKE

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA

Ischemic stroke, Transient ischemic attack

All genders

18+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

Dompe' Reparixin study

A multinational, multicentre, randomised, doubleblinded, placebo-controlled, parallel-group phase III trial Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19.

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

AN2 EBO301 MAC Study

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

Mycobacterial disease

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

Moderna mRNA 1273 study

A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

COVID-19

All genders

0-12

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

Letermovir for secondary prophylaxis for CMV disease in solid organ transplant recipients

A pilot trial of the tolerability and clinical effectiveness of letermovir when used for secondary prophylaxis to prevent recurrent cytomegalovirus disease in solid organ transplant recipients

Cytomegalovirus infection

All genders

18-75

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

SUMMIT MAX

A Prospective, Randomized, Controlled, Interventional Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPoint^® Reperfusion System for Aspiration Embolectomy in Acute Ischemic Stroke Patients

Stroke

All genders

18-85

Recruiting now

Department of Neurosurgery

Tufts Medical Center

Learn more

AbbVie EAISE

A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke

Stroke

All genders

30-80

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

PFO-PAS

Amplatzer PFO Occluder Post Approval Study (PFO PAS)

Stroke

All genders

18-60

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

ASPIRE

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Intracerebral hemorrhage

All genders

18+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

ARCADIA

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

Stroke

All genders

45+

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A multinational, multicentre, randomised, doubleblinded, placebo-controlled, parallel-group phase III trial Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19.

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

A pilot trial of the tolerability and clinical effectiveness of letermovir when used for secondary prophylaxis to prevent recurrent cytomegalovirus disease in solid organ transplant recipients

A Prospective, Randomized, Controlled, Interventional Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPoint^® Reperfusion System for Aspiration Embolectomy in Acute Ischemic Stroke Patients

A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke

Amplatzer PFO Occluder Post Approval Study (PFO PAS)

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke